Trying to make decisions about which healthcare technology to acquire, the appropriate timing of these acquisitions, and the utilization of these products can feel like an endless game show episode. The movement toward a value-based healthcare delivery system has left healthcare organizations scratching their heads to come up with the answers about how to make the most cost-efficient and clinically effective purchases and deployment decisions that will enhance patient outcomes without negatively affecting the bottom line. Both clinical leadership and supply chain coordinators want to know: can I phone a friend? Do I have a 50/50?
The answer to both is “yes.” This October, I am honored to present for my fifth year at the Association of Healthcare Value Analysis Professionals’ (AHVAP) 13th Annual Education Conference & Supplier Showcase. The topic for 2016 is “Making Decisions When There Is Poor or Inadequate Evidence: 10 Questions to Ask.” Prior to the conference, we've received a significant amount of feedback from physicians and supply chain leaders alike, concerned with a lack of engagement between them when it comes to making healthcare technology decisions. While each of the 10 questions from the presentation speak to this concern, let’s look at just a few that address the ways in which Hayes helps to bridge that gap.
Is There Any Evidence Confirming that This Technology Improves Patient Outcomes?
Provisions in the Affordable Care Act (ACA) now encourage comparative effectiveness research (CER), as well as the collection of outcomes and effectiveness data from multiple sources. If studies are found to be well designed and implemented, the data will provide evidence of the clinical value of various treatments and interventions and aid in determining the value of those health technologies.
Subscribers to the Hayes Knowledge Center have access to our Comparative Effectiveness Reviews, which assess the relative benefits and harms of two or more devices, drugs, biologics, tests, or treatments. Access to these head-to-head comparisons allows providers and technology assessment committees to make more informed technology acquisition decisions.
Is Lack of Evidence Likely to Continue? What Can You Reasonably Extract from Available Evidence?
Providers: you know the scenario. A patient comes to see you, requesting a new treatment, drug, or device they heard about on the radio or saw advertised in a magazine. You may have even been excited about the prospect of some new but unproven technology yourself, but you’ve hesitated to bring it to your organization because while clinical trials might be underway, the current evidence is lacking in information regarding safety and efficacy. Hayes offers two solutions: Prognosis and the Health Technology Brief (HTB).
Prognosis is a service that scans media outlets, peer-reviewed journals, and regulatory agencies for leads on new and emerging technologies in the regulatory approval process, or that very have recently been approved for marketing by the FDA or reimbursement by the Centers for Medicare & Medicaid Services (CMS).
The HTB’s are assessments of emerging technologies (FDA approved) or established technologies with new applications for which there is limited published and peer-reviewed evidence. HTB reports come with the industry-standard Hayes Rating. Both Prognosis and HTB reports are included with a subscription to the Hayes Knowledge Center.
Let Hayes Be Your “Life Line.”
Finding the evidence to support healthcare technology decisions can be a time-consuming and difficult process. Supply chain coordinators, value analysis professionals, and clinical leadership alike need independent, unbiased evidence to make acquisition and utilization decisions that are both cost-effective and have a positive impact on patient outcomes. Hayes provides fiercely unbiased evidence analyses to help answer the million-dollar questions and bring you one step closer to winning the game.
Want answers to the rest of the questions? Download our e-book, “Making Healthcare Technology Decisions with Limited Evidence” by clicking below.